MRK•benzinga•
Merck Plans Regulatory Submission For Two-Drug Regime For HIV Infection By Mid-2025
Summary
Merck's DOR/ISL met primary efficacy and safety goals in two Phase 3 HIV trials. Marketing applications are planned for mid-2025.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on March 12, 2025 by benzinga